New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
09:35 EDTLVS, CELG, SCTY, GOOG, NFLX, V, TSLA, SIRI, AAPLActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL SIRI TSLA V GOOG CELG NFLX SCTY LVS
News For AAPL;SIRI;TSLA;V;GOOG;CELG;NFLX;SCTY;LVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | all recent news | >>
July 15, 2015
09:18 EDTGOOGAdobe's Flash disabled by Google due to security worries, WSJ says
Just days after Facebook's (FB) top security executive called on Adobe (ADBE) to discontinue its Flash animation player, Google’s (GOOG) Chrome and Mozilla’s Firefox browsers blocked old versions of the software on Tuesday after reports that hackers were using a security flaw to infiltrate computers, reported The Wall Street Journal's "Digits" blog. Firefox and Chrome will allow Flash to run again if it is updated with the patch Adobe released Tuesday morning, the report noted. Reference Link
08:46 EDTCELGCelgene price target raised to $191 from $163 at BMO Capital
Subscribe for More Information
08:40 EDTCELGCelgene acquisition positive, says JMP Securities
Subscribe for More Information
08:27 EDTGOOGAdobe says Google display ad strategy underperforms Facebook in Q2
In its "Digital Advertising & Social Intelligence Report" for Q2, Adobe (ADBE) wrote that Facebook's (FB) display ad changes doubled its click-through-rates, or CTRs, year-over-year in the quarter, while Google's (GOOG) display targeting changes reduced its number of ads seen by 22% compared to the prior year and its CTRs were up "only" 24% compared to the same period of last year. The report also contends that the "Mobilegeddon" fears regarding Google's changes to favor mobile friendly sites came true, noting that sites with low mobile engagement saw up to a 10% decrease in organic traffic after the changes were made by the search giant. Reference Link
07:59 EDTGOOGGoogle price target raised to $710 from $614 at B. Riley
Subscribe for More Information
07:58 EDTCELGAnalysts break down impact of $7.2B Receptos buyout
After Celgene (CELG) announced last night that the company has agreed to acquire Receptos (RCPT) for $232 per share in cash, or a total of about $7.2B net of cash acquired, research firms have chimed in with their opinions on how the proposed deal may impact others in the biotech space. Receptos key asset is Ozanimod, which is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. DERIVATIVE CALLS: Piper Jaffray analyst Edward Tenthoff told investors that he views Celgene's deal for Receptos as good for Arena Pharmaceuticals (ARNA). The analyst notes that Arena's APD334 is already showing dose-dependent decreases in circulating lymphocyte counts and that the company will initiate Phase II studies in ulcerative colitis and Crohn's disease this year. Tenthoff reiterates an Overweight rating and $7.50 price target on Arena, which has a market capitalization around $1B and closed yesterday up 8c to $4.47. In its own note to investors this morning, Nomura said Celgene's deal could put downward pressure on Biogen's (BIIB) long-term multiple sclerosis estimates. Nomura's M. Ian Somaiya contended that one-year Phase II efficacy data for Ozanimod looked as good as Novartis’s (NVS) Gilenya and Biogen's Tecfidera’s Phase III at year 2. Somaiya also wondered if rival Gilead (GILD) could be "looking for something bigger" than Receptos for its own deal, telling investors that the firm views Incyte (INCY) as Gilead's most likely takeout target. Incyte's shares closed up $4.46 at $117.46 yesterday, giving the company a market cap of about $20B. RIVAL BID?: Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos, noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos told investors she sees "plenty" of potential upside to justify a rival bidder stepping in and reiterated the firm's Outperform rating on Receptos shares. PRICE ACTION: In pre-market trading, Receptos rose 10% to $228.61 while Gilead gained 1.4% to about $119 per share.
07:57 EDTCELGCelgene price target raised to $150 from $135 at RBC Capital
Subscribe for More Information
07:55 EDTCELGReceptos acquisition a 'great deal' for Celgene, says UBS
Subscribe for More Information
07:46 EDTCELGCelgene acquisition of Receptos will be viewed favorably, says Baird
Baird believes Celgene's (CELG) acquisition of Receptos (RCPT) will be viewed favorably by the Street, as the firm sees the price as attractive enough to move the needle for Celgene in the long term. Baird reiterated its Outperform rating and raised its price target to $162 from $139 on Celgene shares.
07:43 EDTCELGReceptos volatility flat into Celgene acquiring for $7.2B
Subscribe for More Information
07:38 EDTNFLXNetflix July volatility increases into Q2 and outlook
Netflix July call option implied volatility is at 108, August is at 49, September is at 42, compared to its 52-week range of 16 to 39, suggesting large near term price movement into the expected release of Q2 results today.
07:09 EDTCELGCelgene may face rival bidder for Receptos, says Wedbush
Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos (RCPT), which has agreed to a $232 per share takeover deal with Celgene (CELG), noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Receptos' Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos, who told investors she sees "plenty" of potential upside to justify a rival bidder stepping in, reiterated the firm's Outperform rating and $348 acquisition value on Receptos shares.
07:04 EDTCELGCelgene volatility low into acquiring Receptos for about $7.2B
Subscribe for More Information
06:39 EDTAAPLApple to release new iPod touch, 9to5Mac reports
Subscribe for More Information
06:33 EDTAAPLApple 'in touch' with Iranian distributors to sell products there, WSJ reports
Subscribe for More Information
06:32 EDTTSLATesla buys 2,000 extra acres for Nevada factory, WSJ reports
Tesla has almost tripled its land holdings in Nevada recently, having bought nearly 2,000 additional acres near Reno as it works on a factory intended to build batteries for electric cars and stationary backup batteries, the Wall Street Journal reports. Tesla originally bought 1,000 acres last year, though that agreement including options to purchase additional land, the report says. Reference Link
06:30 EDTGOOGGoogle July volatility elevated into Q2 and outlook
Google July call option implied volatility is at 35, August is at 23, September is at 21 compared to its 52-week range of 16 to 39, suggesting large near term price movement into the expected release of Q2 results on July 16.
06:28 EDTCELGCelgene price target raised to $175 from $160 at Deutsche Bank
Subscribe for More Information
05:59 EDTCELGPiper views Receptos buyout as good for Arena
Piper Jaffray analyst Edward Tenthoff views Celgene's (CELG) acquisition of Receptos (RCPT) as good for Arena Pharmaceuticals (ARNA). Tenthoff views Arena as a "derivative call" on the deal with the company's APD334 already showing dose-dependent decreases in circulating lymphocyte counts. Arena will also initiate Phase II studies in ulcerative colitis and Crohn's disease this year, the analyst points out. Receptos' ozanimod is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. Tenthoff reiterates an Overweight rating on Arena with a $7.50 price target. The company has a market capitalization around $1B and closed yesterday up 8c to $4.47
05:52 EDTCELGReceptos deal 'another good move' for Celgene, says Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use